Eli Lilly's Stock Soars Amid Growth and Innovation
Originally Published 2 months ago — by Barron's
Eli Lilly's stock reached a new high after a positive analyst upgrade and a deal with the U.S. government to lower drug prices, which is expected to boost obesity drug adoption and future drug launches, despite some concerns over valuation and competition.